Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/30/2025 11:45 PDT] EOM Pharmaceuticals Holdings, Inc. (NYSE:IMUC), Down By 100% ($0.18) From $0.18 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/30/2025 11:45 PDT] EOM Pharmaceuticals Holdings, Inc. (NYSE:IMUC), Down By 100% ($0.18) From $0.18 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/30/2025 07:03 PDT] IMUC Expected to Trade Down After Bearish Patterns Develop
• [10/29/2025 06:54 PDT] IMUC Expected to Trade Down After Bearish Patterns Develop